Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis.
A 35-year-old woman with a history of indeterminate colitis developed symptoms of multiple sclerosis after treatment with infliximab. Neurologic examination confirmed upper and lower extremity motor and sensory deficits. MRI showed multiple enhancing white matter lesions distributed throughout her brain as well as her thoracic spine. There may be a link between inflammatory demyelinating disease of the central nervous system and anti-tumor necrosis-alpha therapy. This case report describes the onset or worsening of a demyelinating process after the initiation of infliximab therapy in a patient with indeterminate colitis.
Enayati
Pedram J
PJ
Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90048, USA.
Papadakis
Konstantinos A
KA
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D003092:Colitis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism; D013116:Spinal Cord / Q000473:pathology; D013909:Thorax; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab